For Healthcare Professionals
Advancing Skin Cancer Detection with Clinical Evidence
At SkinVision, our mission is to improve early skin cancer detection through robust, peer-reviewed clinical research, supported by large-scale real-world validation.
GDPR Compliant
ISO 13485 Certified
CE Class lla MDR Approved
Featured Clinical Studies
Peer-reviewed research demonstrating clinical validity and real-world impact
Validation Study
The ACCURACY Study
Dermatology, 2022 | Sangers T et al.
To validate the diagnostic accuracy of the SkinVision app, which uses a convolutional neural network (CNN) to detect premalignant and malignant skin lesions
Lesions asesessed
785
Sensitivity
86.9%
Specificity
80.1%
Real-World Evidence
Healthcare Claims Study
NPJ Digital Medicine, 2023 | Smak Gregoor et al.
To assess the impact of the SkinVision app on dermatological healthcare consumption in a population-based setting.
Increased detection
+32%
Sensitivity
>90%
Specificity
89%
How the SkinVision Algorithm works
Advanced AI combined with expert dermatologist review for reliable assessment
1
Image Capture
Users capture high-quality, standardized images using our smart camera interface with guided positioning.
2
AI Risk Assessment
ResNet-50 CNN analyzes the image and provides risk indication: High risk, Low risk, or In review.
3
Quality Assurance
All high-risk and in-review cases undergo secondary review by our expert dermatology panel.
4
Results & Guidance
Users receive clear guidance on next steps, whether monitoring or seeking medical consultation.
Model Performance
Trained on 200,000+ dermatologist-labeled images from diverse demographics
91-96%
Sensitivity
Ability to correctly identify malignant lesions
89%
Specificity
Ability to correctly identify benign lesions
92.1%
Consistency
Stable outputs on similar images
Research Pipeline
At SkinVision, our commitment to continuous improvement is driven by ongoing research and the integration of real-world data. We are actively refining our AI algorithm through targeted investigations that focus on:
1
High-risk lesion detection
2
Performance across diverse skin types and demographics
3
Longitudinal studies evaluating long-term outcomes
Upcoming studies
2025 - 2028
Cost-effectiveness projects
HE modeling and large data collections, Investigator initiated
Status: In Progress
2025 - 2026
GP reader & Derm panel evaluation
Investigator initiated
Status: In Progress
2025 - 2027
US Pivotal study
Sponsor initiated
Status: Planned
2025 - 2027
Darker skin type (IV - VI) data collection
Investigator initiated
Status: Planned
For clinical related questions and information, please contact our clinical team Valentina Barone and Wim Laloo
clinical.affairs@skinvision.com